Nutritional composition for improving brain function in phenylketonuria

Patent metadata

Field	Value
Publication number	US-10039732-B2
Application number	US-201414784838-A
Country	US
Kind code	B2
Filing date	Apr 17, 2014
Priority date	Apr 17, 2013
Publication date	Aug 7, 2018
Grant date	Aug 7, 2018

Abstract

The present invention relates to food compositions comprising nutritional composition for use in the treatment or nutritional management of phenylketonuria or hyperphenylalaninemia or for preserving or improving brain function in PKU or hyperphenylalaninemia. The composition comprises a specific protein source, long chain polyunsaturated fatty acids and at least one of uridine or cytidine.

First claim

The invention claimed is:

1. A method for preserving and improving cognitive function and reducing cognitive deficit in phenylketonuria (PKU) or hyperphenylalaninemia patients, comprising administering to said patient in need thereof a nutritional composition comprising:
a. a protein fraction consisting of free amino acids and at least 50 wt % glycomacropeptide, wherein the protein fraction has less than 1.0 wt % of phenylalanine,
b. one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof;
c. docosahexaenoic acid (22:6; DHA) and eicosapentaenoic acid (20:5; EPA), or esters thereof; and
d. choline,
such that, per day,
(i) 0.08-3 g of the cumulative amount of the one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof,
(ii) 400-5000 mg per day of the sum of DHA and EPA and esters thereof; and
(iii) more than 50 mg of choline, is administered.

2. The method according to claim 1 , wherein the protein fraction comprises less than 0.1 wt % phenylalanine based on total protein content.

3. The method according to claim 1 , wherein the nutritional composition is administered to provide 200-600 mg choline per daily dose.

4. The method according to claim 1 , wherein the protein fraction comprises at least 50 wt % glycomacropeptide (GMP) based on the total protein content.

5. The method according to claim 1 , wherein the nutritional composition is a liquid composition further comprising a combination of pectin and at least one indigestible carbohydrate selected from the group consisting of xanthan gum and guar gum.

6. The method according to claim 5 , wherein the viscosity of the nutritional composition is between 5 and 1500 mPa s, at 20° C. and a shear rate of 100/s.

7. A nutritional composition, comprising:
(a) a protein fraction consisting of free amino acids and at least 50 wt % glycomacropeptide, wherein the protein fraction has less than 1.0 wt % of phenylalanine,
(b) a fat fraction comprising 1-40 wt. % docosahexaenoic acid (22:6; DHA) or esters thereof, based on total fatty acids; and 0.5-20 wt. % eicosapentaenoic acid (20:5; EPA) or esters thereof, based on total fatty acids,
(c) 50 to 3000 mg choline per 100 ml of the composition,
(d) 0.08-3 g of the total sum of one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof per 100 ml of the composition, and
(c) optionally, a carbohydrate fraction comprising between 5-70 en % digestible and optionally between 1-5 en % indigestible carbohydrates, based on the total energy content of the composition.

8. The nutritional composition according to claim 7 , wherein the nutritional composition comprises between 30-65 en % protein, and between 1 and 15 en % fat, and between 1 and 60 en % digestible carbohydrates based on the total energy content of the composition, and wherein the composition is a liquid with a total caloric density between 50 and 300 kcal/100 ml.

9. The nutritional composition according to claim 7 , wherein choline is present in an amount of 200-1000 mg per 100 ml.

10. A method for dietary management of PKU or hyperphenylalaninemia patients, comprising administering a supplement comprising (a) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof;
(b) docosahexaenoic acid (22:6; DHA) and eicosapentaenoic acid (20:5; EPA); and (c) choline, in conjunction with a nutritional composition comprising a protein source substantially devoid of phenylalanine, wherein the total daily intake of both the supplement and the nutritional composition is between 40-80 g protein, between 25-45 g carbohydrates, 0.08-3 g per day of the cumulative amount of the one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof, 400-5000 mg per day of the sum of DHA and EPA and esters thereof; and (c) more than 50 mg per day of choline.

11. A method for preserving and improving cognitive function and reducing cognitive deficit in phenylketonuria or hyperphenylalaninemia patients or preserving and improving cognitive function and reducing cognitive deficit associated with phenylketonuria or hyperphenylalaninemia, comprising administering to said patient in need thereof the nutritional composition according to claim 7 .

12. A method for preserving and improving cognitive function and reducing cognitive deficit in phenylketonuria or hyperphenylalaninemia patients, comprising administering to said patient in need thereof a supplement comprising (a) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; (b) docosahexaenoic acid (22:6; DHA) and eicosapentaenoic acid (20:5; EPA); and (c) choline, wherein said supplement is administered in conjunction with a nutritional composition comprising a protein source substantially devoid of phenylalanine, wherein the total daily intake of both the supplement and the nutritional composition is between 40-80 g protein, between 25-45 g carbohydrates, 0.08-3 g per day of the cumulative amount of the one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof, 400-5000 mg per day of the sum of DHA and EPA and esters thereof; and (c) more than 50 mg per day of choline.

13. The method according to claim 12 , comprising administering choline in an amount of 200-1000 mg per 100 ml per day.

14. A method for treatment or providing nutritional management of hyperphenylalaninemia patients or phenylketonuria patients, said method comprising administering to said patients a composition comprising:
a. a protein fraction consisting of free amino acids and at least 50 wt % glycomacropeptide, wherein the protein fraction has less than 1.0 wt % of phenylalanine,
b. one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof;
c. docosahexaenoic acid (22:6; DHA) and eicosapentaenoic acid (20:5; EPA), or esters thereof, and
d. choline, and
optionally a carbohydrate fraction comprising between 5-70 en % digestible carbohydrates based on the total energy content of the composition,
such that, per day,
(i) 0.08-3 g of the cumulative amount of the one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof,
(ii) 400-5000 mg per day of the sum of DHA and EPA and esters thereof; and
(iii) more than 50 mg of choline, is administered.

15. A method for treatment of hyperphenylalaninemia patients or phenylketonuria patients, said method comprising administering said patients a composition supplement comprising (a) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; (b) docosahexaenoic acid (22:6; DHA) and eicosapentaenoic acid (20:5; EPA); and (c) choline, wherein said supplement is administered in conjunction with a nutritional composition comprising a protein source substantially devoid of phenylalanine, wherein the total daily intake of both the supplement and the nutritional composition is between 40-80 g protein, between 25-45 g carbohydrates, 0.08-3 g per day of the cumulative amount of the one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof, 400-5000 mg per day of the sum of DHA and EPA and esters thereof, and (c) more than 50 mg per day of choline.

16. The nutritional composition according to claim 6 , wherein the nutritional composition comprises uridine in an amount of 100-2000 mg per 100 ml.

17. The method according to claim 12 , wherein the nutritional composition comprises uridine in an amount of 100-2000 mg per 100

Assignees

• Nutricia Nv

Inventors

• Van Anholt Rogier Daniël
• Attali Amos

Classifications

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• A61P25/00

  Drugs for disorders of the nervous system · CPC title

• A61K31/198 Primary

  Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00) · CPC title

• A61K31/7072

  having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine · CPC title

• A23L33/12 Primary

  Fatty acids or derivatives thereof · CPC title